<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397432</url>
  </required_header>
  <id_info>
    <org_study_id>HangzhouNU</org_study_id>
    <nct_id>NCT04397432</nct_id>
  </id_info>
  <brief_title>Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study</brief_title>
  <acronym>SELECT-1</acronym>
  <official_title>Synergistic Real-world Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer（NSCLC）：Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tian Xie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LinkDoc Technology (Beijing) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Normal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a nationwide, multicenter and retrospective cohort study. The purpose of this study&#xD;
      is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated&#xD;
      advanced non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 9.2%-45.8% of Chinese patients with Non-small cell lung cancer were positive for EGFR&#xD;
      gene mutation. Gefitinib, Erlotinib, Icotinib, Afatinib showed efficacy superior to that of&#xD;
      chemotherapy in the treatment of EGFR mutation positive advanced NSCLC, and lower rates of&#xD;
      serious adverse events. However, after a median of 8 to 13 months of disease control,&#xD;
      patients ultimately progress due to acquired resistance of EGFR-TKIs. Elemene, a&#xD;
      chemotherapeutic isolated from the Chinese medicinal herb Rhizoma Zedoariae, has been shown&#xD;
      to have a comprehensive anti-tumor effect and the potential effect on reversing drug&#xD;
      resistance.&#xD;
&#xD;
      The study is a real-world study and the case records of patients with advanced non-small cell&#xD;
      lung cancer who visited the research centers from January 2014 to December 2017 and met the&#xD;
      inclusion criteria will be collected. Medical data including patient demographic, tumor&#xD;
      characteristics, laboratory examination, history of treatments, adverse reactions, and so on&#xD;
      will be extracted to evaluate the synergistic effect and safety of Elemene plus TKIs in&#xD;
      EGFR-mutated advanced non-small cell lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>June 2021</time_frame>
    <description>OS was defined as the interval from the date of the administration of the first-dose TKIs to date of death from any cause, or the date of last known follow-up alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>June 2021</time_frame>
    <description>PFS was defined as the interval from date of the administration of the first-dose TKIs to the date of first evidence of disease progression or death, whichever occurs first. Disease progression was defined according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>June 2021</time_frame>
    <description>ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>June 2021</time_frame>
    <description>Disease Control Rate (DCR) = Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KPS score</measure>
    <time_frame>June 2021</time_frame>
    <description>Performance status were measured by Karnofsky Performance Scale (KPS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECOG score</measure>
    <time_frame>June 2021</time_frame>
    <description>Eastern Cooperative Oncology Group (ECOG) performance status adopted the zubrod-ecog-who scoring standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AE or SAE</measure>
    <time_frame>Start of treatment until 30 days after the last dose.</time_frame>
    <description>Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.&#xD;
A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1812</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Elemene plus TKIs</arm_group_label>
    <description>This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKIs only</arm_group_label>
    <description>This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced non-small cell lung cancer and EGFR mutation who visited the&#xD;
        research centers from January 2014 to December 2017 and received TKIs therapy with or&#xD;
        without Elemene.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed advanced non-small cell lung cancer(stage&#xD;
             IIIB~IV).&#xD;
&#xD;
          2. Patients with EGFR mutation.&#xD;
&#xD;
          3. Received EGFR-TKIs at least once.&#xD;
&#xD;
          4. Received Elemene Injectable Emulsion and/or Elemene Oral Emulsion at least once ( only&#xD;
             for Elemene plus TKIs group).&#xD;
&#xD;
          5. Completeness of important outcome measures and medical records related to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accompanied by other active tumors.&#xD;
&#xD;
          2. The researchers did not consider it appropriate to participate in this study for other&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziping Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tian Xie, PhD</last_name>
    <phone>+86-13606707928</phone>
    <email>xbs@dljg.sina.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinbing Sui, PhD</last_name>
    <phone>+86-13486192868</phone>
    <email>hzzju@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhao</last_name>
      <phone>+86-18255179769</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panjin Central Hospital</name>
      <address>
        <city>Panjin</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinghua Gao</last_name>
      <phone>+86-18102487506</phone>
      <email>gaoqinghuawl@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Yangcheng County</name>
      <address>
        <city>Jincheng</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Wei</last_name>
      <phone>+86-13372907199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Xie</last_name>
      <phone>+86-18428028235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiyuan Ding</last_name>
      <phone>+86-13575467709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongde Hospital of Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengquan Feng</last_name>
      <phone>+86-17348393780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhibing Wu</last_name>
      <phone>+86-17348393780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhouwan Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaifeng Wang</last_name>
      <phone>+86-13588088469</phone>
      <email>kaifengw@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongfang Hospital Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <zip>100078</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanwang Li, PhD</last_name>
      <phone>+86-13301212676</phone>
      <email>quanwangli@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziping Wang</last_name>
      <phone>+86-13301212676</phone>
      <email>wangzp2007@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Feng</last_name>
      <phone>+86-18322012056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Huanxing Chaoyang District Beijing</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong Dai</last_name>
      <phone>+86-13522257349</phone>
      <email>daizhong1102@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang</last_name>
      <phone>+86-18423038207</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Wu</last_name>
      <phone>+86-18917763370</phone>
      <email>wq13311772201@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Li</last_name>
      <phone>+86-18521301790</phone>
      <email>lzwf@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailong Wang</last_name>
      <phone>+86-15011015864</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenxue Zhang</last_name>
      <phone>+86-15011015864</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hangzhou Normal University</investigator_affiliation>
    <investigator_full_name>Tian Xie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Elemene, TKI, EGFR, Real world study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

